chrisvoncsefalvay/vaers-outcomes huggingface dataset:
This spontaneous report as received from a registered nurse refers to an unknown of patients of unknown patient demographics. The patients medical history and current conditions is not reported. It was reported that approximately on an unknown in 2014 (reported as between February 5, 2014 and June 9, 2014) the patient were vaccinated with LIQUID PEDVAXHIB of unknown dose and route of administration (Lot # and batch # was not reported) that had been improperly stored. No adverse effects reported. The outcome is unknown. No product quality issue was reported. Additional information has been requested.
Fever, generalized pain, nausea, disturbed sleep: onset 4 hours after vaccine. Diarrhea following day. Severe generalized rash: 3 days after vaccine  Treatment with epi, benedryl, and solumedrol
This case was reported by a consumer via call center representative and described the occurrence of headache in a 64-year-old female patient who received SHINGRIX for prophylaxis. Previously administered products included SHINGRIX with an associated reaction of headache (not quite as bad as after the 2nd dose. For tolerance after 1st dose, refer case US2018GSK120405). On 27th June 2018, the patient received the 2nd dose of SHINGRIX. On 27th June 2018, several hours after receiving SHINGRIX, the patient experienced headache, general body pain and queasy. On an unknown date, the outcome of the headache, general body pain and queasy were unknown. It was unknown if the reporter considered the headache, general body pain and queasy to be related to SHINGRIX. Additional details were provided as follows: This case was reported via a live click to chat. The patient was in good health condition before receiving the vaccine. The patient received SHINGRIX in the afternoon. The patient experienced headache, body aches and general queasiness on the night of vaccination and the next day morning as well. The patient asked if she can take TYLENOL or ibuprofen for this reaction and stated that, she could not find this information in the paperwork of the vaccine. The patient was advised to discuss medical concerns and symptoms with a physician or other healthcare provider to evaluate the medical conditions and treatment. The patient stated, she would call the pharmacy to seek advice. This case was linked with the case US2018GSK120405, reported by the same reporter for the same patient.
The patient is a 17 year, 6 month old male who is here for a well exam. Here with mother. Child eats 3 meals plus snacks and picky eater. Child drinks whole milk. Child drinks 16-24 oz milk per day. Child received OTC multivitamin (occationally). Hearing screening: no concerns with hearing. Vision screening: had vision screening in the past 12 months. Child had no reaction to previous immunization. Discussed safety issues appropriated to age and made recommendations. Confirmed smoke detector in home, wears seat belt, visits dentist regularly and knows how to swim; and no wears helmet when riding bike. Child is enrolled in eleventh grade (junior). Guardian reports no problems at school. Family denies information on community resources at this time. Additional reasons for visit: Teen Risk Assessment is described as the following: In the past 12 months patient has vaped or juuled (quit one month ago) and had anxiety or worries that interfere with sleep or other activities, but not smoked cigarettes, chewed tobacco, drank any beer or wine or other alcohol, smoked marijuana, vaped or waxed marijuana or THC oil, eaten edible candy or brownies with marijuana or THC oil, use other street drugs, had problems with anger control or intentionally harmed self. In the past 2 weeks patient has not had problems with feeling down or depressed or hopeless or little interest or pleasure in doing things. Patient denies having sexual intercourse or oral sex.
received infusion after and now cannot receive the second dose for 90 days; tested positive for covid-19; This spontaneous case was reported by a consumer and describes the occurrence of SARS-COV-2 TEST POSITIVE (tested positive for covid-19) and OFF LABEL USE (received infusion after and now cannot receive the second dose for 90 days) in a 76-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On 26-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 12-Mar-2021, the patient experienced SARS-COV-2 TEST POSITIVE (tested positive for covid-19). On 13-Mar-2021, the patient experienced OFF LABEL USE (received infusion after and now cannot receive the second dose for 90 days). At the time of the report, SARS-COV-2 TEST POSITIVE (tested positive for covid-19) and OFF LABEL USE (received infusion after and now cannot receive the second dose for 90 days) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No Concomitant and treatment medications were reported.   This case was linked to US-MODERNATX, INC.-MOD-2021-069728 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2021-069728:Wife case
A temperature 101 F all day; This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (A temperature 101 F all day) in a 41-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event (No medical history provided.).   On 08-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 05-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 06-Apr-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced PYREXIA (A temperature 101 F all day). At the time of the report, PYREXIA (A temperature 101 F all day) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 06-Apr-2021, Body temperature: 101 Increased body temperature and 102.8 Increased body temperature.         Concomitant product use was not provided.  Treatment information included Tylenol.  Action taken with mRNA-1273 in response to events was not applicable.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.
NO ADVERSE REACTION REPORTED. A PFIZER VACCINE WAS ADMISNISTERED TO A PATIENT AFTER BUD OF 7/22/22. PATIENT, RECIEVED A PFIZER BOOSTER SHOT 3 DAYS AFTER BUD. The medical/safety team at Pfizer WAS CONTACTED AND indicated THE DISCOVERING PHARMACIST they do have stability but not efficacy data on the adult Pfizer vaccine beyond 72 days when stored in a refrigerator. They recommended that our rph contacts the CDC and inquires about repeating doses for these patients. Speaking with the CDC employees, our rph was given the same information as above and referred to the immunization division at the DOH.  Our rph contacted the DOH in the state, but she was asked to confer with either PHARMACY Medical Doctor or the standing order physician. Our rph was able to interact with the latter, and she was given the guidance of re-vaccinating . In the context of the guidance from the standing order physician, the patient will need to repeat the dose. Regular schedules for series completion/booster doses will be observed if/when warranted.
itching in back; few hives/hives between knuckles; swamped in sweat during night; whole body was in pain; could not get out of bed; headache between neck and head; This spontaneous case was reported by a consumer and describes the occurrence of PRURITUS (itching in back), URTICARIA (few hives/hives between knuckles), HYPERHIDROSIS (swamped in sweat during night), MYALGIA (whole body was in pain) and FATIGUE (could not get out of bed) in a 65-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 010421A) for COVID-19 immunisation. The occurrence of additional non-serious events is detailed below.     Concomitant products included MULTIVITAMINS [VITAMINS NOS], VITAMIN D3, CYANOCOBALAMIN (B-12) and VITAMIN E [VITAMIN E NOS] for an unknown indication.    On 26-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PRURITUS (itching in back), URTICARIA (few hives/hives between knuckles), HYPERHIDROSIS (swamped in sweat during night), MYALGIA (whole body was in pain), FATIGUE (could not get out of bed) and HEADACHE (headache between neck and head). The patient was treated with DIPHENHYDRAMINE CITRATE, IBUPROFEN (ADVIL PM [DIPHENHYDRAMINE CITRATE;IBUPROFEN]) for Adverse event, at a dose of 1 dosage form. At the time of the report, PRURITUS (itching in back), URTICARIA (few hives/hives between knuckles), HYPERHIDROSIS (swamped in sweat during night), MYALGIA (whole body was in pain) and FATIGUE (could not get out of bed) had resolved and HEADACHE (headache between neck and head) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
Information has been received from a health professional concerning a 17 year old female with no medical history or allergies, who on 20 Aug 2006 and 20 Oct 2006 was vaccinated IM with a first and second 0.5mL dose of Gardisal (yeast), respectively (first dose lot # 654540/0800F and second dose lot # 653736/0868F). There was no concomitant medication. On 20 Aug 2006, the patient experienced nausea and emesis. On 20 Oct 2006, the patient again experienced immediate nausea and vomiting. On 21 Oct 2006 the patient experienced low grade fever. Unspecified medical attention was sought. No diagnostic laboratory studies were performed. Subsequently, the patient recovered from emesis. At the time of this report, the patient's low grade fever persisted and the outcome of nausea was unknown. No product quality complaint was involved. Additional information has been requested.
Chest CT right pleural effusion, and COVID pneumonia, CRP 22. LE edema. RA oxygen saturation 82 % 15L oxy mask only 89% BiPap will be initiated.
REDNESS AND SWELLING AT SITE OF INJECTION. PATIENT STATED ALSO ITCHING
1 inch local reaction light red in color. No lump. (Varicella right arm).
c/o of throat tightness for about 5 mins after taking the first dose of pfizer vaccine.   pt. is allergic to bee, sulfa. H/O anxiety and takes xanax as needed.  has her Epipen handy.  Symptoms got resolved.  Prior to her leaving the parking lot.   Denies SOB, itching.  No hives or swelling noted in the oral cavity.  V/S O2 sat 98, R-18.  Hr 86, advised to r/u PCP if symptoms reoccurs
she got Covid virus; she got Covid virus; This is a spontaneous report from a Pfizer-sponsored program via a contactable Nurse reported for herself. A female patient of an unspecified age received the first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE; Lot number: unknown), via an unspecified route of administration on an unspecified date at SINGLE DOSE for covid-19 immunisation. The patient medical history and concomitant medications were not reported.  Patient reported that she already got the first dose of her COVID Vaccine and after that she got COVID virus on an unspecified date. Patient lab data included she got COVID virus on an unspecified date. She wanted to know if she should continue to get her 2nd dose or what she should do. Outcome of the event was unknown.  Information on the lot/batch number has been requested.; Sender's Comments: The efficacy of a drug varies from patient to patient and can be affected by different factors; however, a contributory role of the suspect product bnt162b2 to the reported drug ineffective and COVID-19 cannot be ruled out.
Immediate rapid heart rate 120 bpm I sat down,  put feet up, slow breathing, monitored heart rate for 30 minutes. Heart rate slowed down to 70. I was light headed for about 3 hours.   Having more pvc's or heart flip flops than usual.
full body hives with severe itching; full body hives with severe itching; This is a spontaneous report from a contactable physician (reported for herself). A 32-year-old female patient received the second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: EL1283), via an unspecified route of administration (left arm) on 10Jan2021 11:30 at single dose for Covid-19 immunization. The patient's medical history reported as none; no known allergies. Concomitant medications were not reported. The patient previously received the first dose of BNT162B2 on an unspecified date for Covid-19 immunization. The patient was not diagnosed with COVID-19 prior to vaccination. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine.  The patient experienced full body hives with severe itching on 11Jan2021 (16:00). The patient received Loratadine and Benadryl as treatment for the events. The outcome of events was recovering. The patient has not been tested for COVID-19 since the vaccination.
Received MENACTRA on 10/24/2017, later that evening began with headache, body ache, stiff neck "felt like I was hit by a truck". Next day continued with those symptoms, then trouble breathing and rapid heart rate. Saw family doctor who ran blood tests and potassium was low. Was given fluids and extra potassium but symptoms continued over the weekend. October 30, went back to doctor for shortness of breath and rapid heart rate. Echo performed was negative. Chest X ray negative. CT scan with and without contrast was negative. November 1st, Dr. told mother that child's body aches, shortness of breathe and rapid heart rate was pleurisy caused by the MENACTRA shot. He referred her to a pulmonologist. Mother is a nurse and demanded a VAERS report to be completed.
patient states fever, cold sweats, join/muscle pain, headache, and rash at injection site.  Resolved in 1 day
Case number PHEH2012US016244 is an initial spontaneous report received from a pharmacist on 15 Aug 2012. This case refers to a patient of unspecified age and gender. The patient was vaccinated only with MenCYW component of MENVEO vaccine (batch number: X11032) intramuscularly on 15 Aug 2012. No adverse event was reported following this drug administration error.
Fever 12/27/18. Rash 12/28/18 -> 12/29/18 - 48hrs. Swollen lymph node 1/3/19.
Reportedly complained of shortness of breath and "not feeling right" to work supervisor on  on 11/12/2021  Collapsed in front of sister on 11/18/2021, transported to hsopital by EMS, pronounced dead at hopsital on 11/18/2021
Rash; This is a spontaneous report from a non-contactable nurse. A 78-years-old female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN5318), intramuscular on an unspecified date (at the age of 78-years-old) as 1st dose, single for COVID-19 immunisation. The patient medical history was not reported. The patient's concomitant medications were not reported.  The patient experienced rash, developed the next day after receiving her first Pfizer vaccine, occurring across her midsection of abdomen. It lasted for 2 weeks. No other problems with the vaccination. Reports that her physician recommended that she continue with second dose as scheduled. The outcome of event was unknown.   No follow-up attempts are possible. No further information is expected.
Rash in the form of small raised bumps and hives on torso, itching appeared 2 days after vaccine was taken, after fever broke. Antihistamine (children's zyrtec) was administered for 3 days. Rash did not change in appearance, but itchiness went away.
My history with the Anthrax shot has always resulted in what I could call Severe symptoms. During the immunization I was asked if I had any severe symptoms in the past and I said Yes. I was then given a sheet that showed this reporting avenue (www.vaers.hhs.gov). Historical symptoms include fever for 24 to 48 hours. Severe aches, chills, sweat at night and at times mild nausea. I have experienced these symptoms with every Anthrax vaccination. In general I now clear the next 48 hours after a vaccination because I am unable to do anything else. During this most recent vaccination (6th in series) symptoms were the same. I call them severe because they are the most-sick I feel I have ever experienced by any illness at any time in my life. Fever started at about 2230 hrs on Thursday 27SEPT2018 and at its highest measured with our electronic ear thermometer in each ear and averaged peaked at 101.8°F (Friday ~2200 hrs). Wife is aware of reactions and is under instructions to take me to ER if fever uncontrollable or hits 102°F. Again had severe aches and pains. Had moderate swelling and pain at injection site. Generally unable to use that arm. My other injection site (Typhoid) was very mild and recovered nicely. Treated fever with over the counter methods and able to eventually get control of it. Fever started to go down at about 0100 hrs, Saturday 29SEPT2018.
Information has been received from a physician concerning a 49 year old female with a history of asthma who on 30-SEP-2008 was given a 0.5ml dose of PNEUMOVAX (Lot # 660685/0619X) subcutaneously for vaccination.  Concomitant therapy included ADVAIR, FLONASE, ADDERALL TABLETS, montelukast sodium (Merck) and NECON.  On 01-OCT-2008 the patient developed severe cellulitis.  The patient was seen in the physician's office for a well check up and the cellulitis is described as being 6 inches in diameter.  The patient not recovered from severe cellulitis at the time of report.  Additional information has been requested.
Large painful lump, along with severe bruising, at the injection site.  Still have these symptoms three weeks later.
I started having a headed the evening of 11/29/22; I awoke on 11/30/22 and the headache was still there but had gotten worse, getting a cough. I took a home COVID-19 test that came back positive. I called my doctor's office and head a telehealth visit with my primary care physician. She prescribed the Paxlovid and I was able to start taking it that evening. During the five days I did have different symptoms, I felt warm, low-grade fever, tired, slight sore throat, an occasional cough, runny nose, sneezing, it was more like a cold. I drank plenty of liquids. After the five days the sneezing and cough continued for a few days, I retested with a home COVID-19 test and the test came back negative.
Employee was called for her 2nd Varicella vaccine, she informed me that she just found out she was pregnant, about 9 weeks. This would make her pregnant when she received the vaccine, even though she denied it at the time and sign a consent that states you cannot get vaccine if you are pregnant. No issues to date, her OB doctor has been notified.
on 2/21/2021, I noticed vaccination site was slightly sore again like it had been in days after receiving vaccine and felt a little firm.  On 2/22 I felt a slight discomfort and looked at my arm, discovering redness.  It looked like a welt approximately 2 inches in height by about 5 inches in length, from the injections site to the inside of my arm.  today, on 2/23/2021, I can see that the welt is about 4 inches in height and about 6 inches in width from the inside of my arm to just past the injections site.  The welt is not raised, nor does it have any signs of rash.  It is just pink.  The lower part of my arm below the elbow is 97.2 degrees and the pink area is 97.5 degrees, with an temperature gun.
On Sunday June 20th I was feeling sick, Fever, body aches, head ache, fatigue. I also had an infection in my gums around my teeth that was burning as if someone poured hot coffee in my mouth non-stop. especially the roof of my mouth and right behind my upper front teeth. After 4 days of trying to sweat it out the night sweats stopped. But my heart rate was at 161 beats per minute but I could not feel my heart beating at all. We went to an urgent care that immediately sent me by ambulance to the hospital. Right away they got my heart rate under control but they spent 4 more days trying fight the infection. Finally on June 29th I was well enough to go home.
Fluarix administered to pregnant patient  (Fluarix dose 6 weeks ago); Fluarix administered to pregnant patient (today); 1st dose 6weeks ago, 2nd 11nov2022; This prospective pregnancy case was reported by a nurse via call center representative and described the occurrence of maternal exposure during pregnancy in a 24-year-old female patient who received Flu Seasonal QIV Dresden (Fluarix Tetra 2022-2023 season) (batch number 9PG4D, expiry date 30th June 2023) for prophylaxis.   Co-suspect products included flu seasonal qiv dresden pre-filled syringe device (Fluarix Tetra Pre-Filled Syringe Device) injection syringe for prophylaxis, Flu Seasonal QIV Dresden (Fluarix Tetra 2022-2023 season) for prophylaxis and flu seasonal qiv dresden pre-filled syringe device (Fluarix Tetra Pre-Filled Syringe Device) injection syringe for prophylaxis.   On 11th November 2022, the patient received the 2nd dose of Fluarix Tetra 2022-2023 season and Fluarix Tetra Pre-Filled Syringe Device. On an unknown date, the patient received the 1st dose of Fluarix Tetra 2022-2023 season and Fluarix Tetra Pre-Filled Syringe Device. The patient's last menstrual period was on an unknown date and estimated date of delivery was on an unknown date. The patient received Fluarix Tetra 2022-2023 season at an unknown time during the pregnancy. On 11th November 2022, unknown after receiving Fluarix Tetra 2022-2023 season and Fluarix Tetra Pre-Filled Syringe Device and not applicable after receiving Fluarix Tetra 2022-2023 season and Fluarix Tetra Pre-Filled Syringe Device, the patient experienced vaccine exposure during pregnancy. On an unknown date, the patient experienced maternal exposure during pregnancy and vaccine exposure during pregnancy. On an unknown date, the outcome of the maternal exposure during pregnancy, vaccine exposure during pregnancy and vaccine exposure during pregnancy were unknown. The pregnancy was ongoing.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date: 11 NOV 2022 Reporter's comment: This case was reported by nurse. The nurse reported that the pregnant patient received the Fluarix quadrivalent first dose six weeks ago and today that is on 11th November 2022 the patient received the second extra dose. The reporter consented to follow up. Additional supportive information: As adult patient requires only one dose, however received the extra second dose which led to extra dose administered. Note: As per schedule only one dose is required for an adult patient, hence extra dose administered was captured.
Pt experienced an 8 x 6 inch area of erythema and swelling with tenderness at injection site on right thigh. Treated with Keflex, cool compresses and Tylenol.
Intense and overwhelming paranoia, psychological, emotional mental health problems. Overwhelming anxiety inability to speak, psychosis, suicidal ideation requiring hospitalization. Onset immediately following administration of injection.